Parkinson's disease: pathogenesis and therapeutic strategies.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms and treatments without original human data or systematic search
PubMed 41949708 · doi:10.1186/s43556-026-00445-0
What was done
This narrative review summarizes the multifactorial pathogenesis of Parkinson's disease (including α-synuclein aggregation, oxidative stress, mitochondrial dysfunction, neuroinflammation, and peripheral-central communication) and outlines current and evolving therapeutic approaches, such as dopamine replenishment, α-synuclein-targeted immunotherapies, iPSC-based regenerative therapies, and gene therapies.
What was found
The abstract reports no numerical findings or quantitative outcomes. It describes the clinical limitation of current dopaminergic agents, which alleviate motor symptoms without halting or slowing disease progression.
Why it matters
It highlights critical bottlenecks in standard Parkinson's disease pharmacotherapy and argues for a shift toward integrated, multi-target, and personalized disease-modifying therapies.
Limits
As a broad narrative review, it presents no original empirical human data. The abstract provides no systematic literature search methodology, study quality appraisal, or quantitative effect sizes for the novel therapies discussed.
Cited by
- supports Parkinson's disease is caused by dopamine depletion in the substantia nigra region of the brain.
- supports Parkinson's disease motor symptoms are caused by the depletion of dopamine in the substantia nigra.